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ABSTRACT  
BACKGROUND: 
There is good evidence for the benefits of short-term cognitive stimulation 
therapy for dementia but little is known about possible long-term effects. 
AIMS: 
To evaluate the effectiveness of maintenance cognitive stimulation therapy 
(CST) for people with dementia in a single-blind, pragmatic randomised 
controlled trial including a substudy with participants taking 
acetylcholinesterase inhibitors (AChEIs). 
METHOD: 
The participants were 236 people with dementia from 9 care homes and 9 
community services. Prior to randomisation all participants received the 7-
week, 14-session CST programme. The intervention group received the weekly 
maintenance CST group programme for 24 weeks. The control group received 
usual care. Primary outcomes were cognition and quality of life.  
RESULTS: 
For the intervention group at the 6-month primary end-point there were 
significant benefits for self-rated quality of life (Quality of Life in Alzheimer's 
Disease (QoL-AD) P = 0.03). At 3 months there were improvements for proxy-
rated quality of life (QoL-AD P = 0.01, Dementia Quality of Life scale 
(DEMQOL) P = 0.03) and activities of daily living (P = 0.04). The intervention 
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subgroup taking AChEIs showed cognitive benefits (on the Mini-Mental State 
Examination) at 3 (P = 0.03) and 6 months (P = 0.03). 
CONCLUSIONS: 
Continuing CST improves quality of life; and improves cognition for those taking 
AChEIs. Further research should evaluate whether long-term CST should be 
provided more frequently than once a week. 
 
Clinical trial registration number ISRCTN26286067 
WORD COUNT: main text 3873 
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INTRODUCTION 
 
There is good evidence for the benefits of cognitive stimulation for people with 
dementia.1 A recent Cochrane review showed that cognitive stimulation 
improved both cognition and quality of life.2 The review concluded the benefits 
of cognitive stimulation enhanced those of medication, which was effective 
whether or not acetylcholinesterase inhibitors (ACHEIs) were prescribed.2 The 
2011 World Alzheimer report concluded “there is strong evidence to support 
cognitive stimulation programmes and these interventions should therefore 
be routinely offered".3  
Cognitive Stimulation Therapy (CST) is a well-defined evidence-based version 
of cognitive stimulation,4 developed following review of a related approach 
known as Reality Orientation (RO).5 We evaluated CST in a pilot trial,6 followed 
by a full trial,4 and developed a manual7 and a training DVD. CST is now used 
widely across the UK and in several other countries. A pilot study of 
maintenance CST which continued for an extra 16 weekly sessions beyond 
the standard seven-week (14-session) CST programme8 found a significant 
improvement in cognitive function compared with CST alone. 
The Cochrane Review found no link between duration or frequency of the 
programme and degree of improvement.2 Some studies have continued 
cognitive stimulation for six months or more,9,10 but there is little evidence about 
how far potential benefits may continue after sessions end. The Cochrane 
Review suggested that effects on cognition continue for at most three months;2 
and another study found no continuing effects at ten months.11  
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This trial aimed to evaluate the effectiveness of Maintenance CST in improving 
cognition and quality of life in people with dementia who have completed 
standard CST, in comparison with standard CST only followed by usual care 
after.12  In addition, a sub-study focused on the effects of maintenance CST on 
people with dementia taking ACHEIs. 
 
METHODS 
Study Design 
This was a single-blind, multi-centre, pragmatic randomised controlled trial 
comparing (1) Maintenance CST groups after completing standard CST  vs (2) 
standard CST only followed by usual care.13 There was no modification in 
design or eligibility criteria from the study protocol12 available at 
http://www.trialsjournal.com/content/pdf/1745-6215-11-46.pdf. 
 
Participants  
Potential centres were screened for eligibility to determine whether there were 
sufficient numbers of potential participants with dementia, using the inclusion 
criteria flow chart. Participants met the DSM-IV criteria for dementia;14 using 
the diagnostic algorithm and most had either Alzheimer’s disease or vascular 
dementia. All had mild to moderate dementia on the Clinical Dementia Rating 
scale;15 could communicate, hear and see well enough to participate in the 
group; had no major physical illness or disability, or diagnosed learning 
disability. All trial participants completed seven weeks of CST4 comprising 
fourteen twice-weekly 45-minute sessions according to the CST manual.8 We 
recruited approximately half of the participants from nine care homes, and half 
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from nine community services which included Community Mental Health 
Teams, day centres and voluntary organisations within London, Essex and 
Bedfordshire. The community centres included four voluntary sector specialist 
dementia day centres and five centres based in local community mental health 
teams for older people. The nine care homes included five provided by Social 
Services, one by the private sector, and three by a voluntary organisation. Of 
21 centres approached, one refused and two had too few eligible participants. 
The study was approved by the Barking & Havering 
Local Research Ethics Committee in October 2008 (ethical approval reference 
number: 08/H0702/68).  
 
Intervention  
After completion of the CST programme participants were randomised within 
each centre to either the (1) intervention group 24-week Maintenance CST 
programme;16  or (2) the usual care control group. Usual care varied across the 
18 centres but other activities were generally available to both groups. 
The Maintenance CST programme was based on the theory of cognitive 
stimulation as applied to the original CST programme.4 guided by the MRC 
framework for complex interventions.17,18  Each Maintenance CST session has 
a specific theme or activity (e.g. current affairs; my life; word games) within a 
consistent structure including orientation-based activity, refreshments and a 
group song. Each group had two facilitators, one from the research team and 
one staff member from the participating centre (i.e. care home or community 
service). All facilitators had at least one year of experience in dementia care, 
and had attended the one-day CST training course.   
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Outcome measures  
Participants were interviewed at baseline, before randomisation, at three 
months (intermediate end point) and after six months (primary end point). 
Researchers collected the proxy ratings of the quality of life measures, the NPI 
and the ADCS-ADL in structured interviews – with staff for participants in care 
homes, and with family carers for those in the community.  
 Primary outcomes 
 (1) Alzheimer’s Disease Assessment Scale – Cognition Subscale 
 (ADAS-Cog). This is the standard cognitive test used in clinical trials for 
 dementia.19 This comprises 11 tasks measuring memory, language, 
 praxis, attention and other cognitive abilities. Lower scores reflect better 
 cognition.  
 (1) Quality of Life in Alzheimer's Disease scale (Qol-AD)20. This is 
 recommended by the European consensus on outcome measures for 
 psychosocial interventions in dementia.21 This covers 13 domains of 
 quality of life, and has good internal consistency, validity and reliability. 
 Higher scores reflect better quality of life.  
 Secondary outcomes  
  (1) Mini-Mental State Examination (MMSE), a brief but widely used   
  generic test of cognitive function.22 This is easier to complete than the 
  ADAS-Cog, but still has good reliability and validity.  
   (2) Dementia Quality of Life scale (DemQoL).23 The DemQoL covers 
  five domains of quality of life and uses both self reporting and rating by 
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  family carer or staff member as proxy. It has good internal consistency, 
  inter-rater reliability and concurrent validity and can generate a  
  measure of utility. 
      (3) Neuropsychiatric Inventory (NPI).24 This assesses 10 behaviours 
 that commonly occur in dementia and has good validity and reliability. 
 Lower scores on this specific measure reflect better behaviour. 
 Total score by frequency x severity of each behaviour  
 (4) Alzheimer's Disease Co-operative Study-Activities of Daily Living 
 (ADCS-ADL). This validated questionnaire assesses functional 
 capacity over the range of dementia severity.25 By summing 
 competencies this measure gives high scores to more able 
 respondents. 
 
Sample size  
Based on the Cochrane Review we estimated effect size for Maintenance CST 
of 0.39 on the ADAS-Cog with power of 80% when using 5% significance level 
and estimating attrition at 15% between baseline and six months. This required 
a sample size of 230 participants randomised at baseline and an estimated 195 
at follow up. With an estimated 60 participants with Alzheimer's disease and 
taking ACHEIs, this provided sufficient numbers for the maintenance 
CST/ACHEIs sub-study to estimate effect size and the feasibility of a full scale 
trial. 
 
Randomisation  
 10 
All participants completed the initial CST programme13 and were then 
allocated at random between (a) the intervention group receiving weekly 
maintenance CST for 24 weeks (maintenance CST group) or (b) the control 
group receiving TAU (TAU group). The North Wales Organisation for 
Randomised Trials in Health (NWORTH) Clinical Trials Unit remotely 
randomised participants in equal proportions between groups after stratifying 
for: centre (community service or care home), whether ACHEI was prescribed, 
and previous CST group (www.bangor.ac.uk/imscar/ 
nworth/). The random allocation sequence was computer-generated and in the 
ratio of 1:1. The NWORTH clinical trials unit emailed the individual allocation to 
the site researcher delivering the intervention and stored the allocation list 
under a secure password, which was not available to any study site staff. The 
scheduled treatment sessions, session records and participant records were 
saved at the site, strictly separated, and distant from the coordinating study 
centre. Once the trial was completed in each centre, records were transferred 
to the coordinating study centre and stored by the study centre administrator 
who was not involved in the assessment process or data analysis. This was in 
order to avoid contamination. The nature of the intervention prevented us from 
blinding participants to their allocated group. However blind researchers 
conducted initial and subsequent interviews, generally in care homes or 
participants’ own homes. The statistician conducting the data analysis was also 
blind to group assignment. 
 
Statistical analysis 
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We used the MACRO system to manage the data (version 3.0.84 on Windows 
2003 R2; Infermed, London, UK, www.infermed.com). Data was entered 
manually and audited internally for typing errors by hand, in order to ensure a 
low error rate. Data was transferred to SPSS version 20 on Windows 7 and 
audited externally by NWORTH with hard copies of assessments. These audits 
entailed cross checking a random 10% sample of the electronic data with the 
paper records to ensure accurate entry. Both random and systematic data entry 
errors were identified and corrected. As the audits were carried out in parallel 
with data entry systematic errors could be corrected at an early stage. For 
participants with some follow-up data, we imputed individual data missing within 
a scale according to the validated rules for that scale; and missing total scores 
by multiple regression on variables including allocated group, age, gender, 
ethnicity, marital status, whether prescribed an ACHEI, staff or family caregiver,  
centre type and individual centre (using random effects). We adopted a forward 
stepwise model, and used baseline scores to help predict scores at three 
months, then both of these to predict scores at six months, since no participant 
missing at three months returned at six months.  
Primary analyses by treatment allocated used analysis of covariance to adjust 
all imputed data for baseline differences in age, gender, ethnicity, marital 
status, prescription of ACHEIs, proportion of family caregivers, individual centre 
(using random effects) and baseline score on the variable under analysis. We 
then estimated the effect of treatment from the resulting model. The 
maintenance CST/ ACHEIs trial platform followed the same methodology as for 
the primary analysis and used the interaction term between ACHEIs and the 
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treatment group to identify any effect between the two factors for the outcome 
measures. 
 
Results 
The recruitment period took place between January 2009 and September 2010. 
The final 24-week follow up was completed in May 2011. Of 272 people with 
dementia that started the CST groups and were considered for the trial, 36 were 
withdrawn (Table 1). We followed up 218 participants (92% of 236; 96% of 
those still alive) at 3 months and 199 (84% of 236; 89% of those still alive) at 6 
months. The CONSORT flowchart (Figure 1) records the reasons for 
subsequent withdrawals. Furthermore the withdrawal rate was similar in both 
arms of the trial.  
Of the 236 participants, 123 were allocated to the Maintenance CST group and 
113 to usual care. The groups were well matched at baseline and 
randomisation avoided imbalances (Table 2). The mean age was 83 years and 
most participants were white females. On average participants allocated to the 
Maintenance CST groups attended 18 of the 24 available sessions.  
 
Outcomes 
At the six-month primary end-point (Table 3),  in terms of primary outcomes, 
the Maintenance CST group had higher scores than controls on self-rated QoL-
AD which reached borderline statistical significance with mean difference 1.78 
(95% CI 0.00 to 3.60; p=0.05). There were no significant differences on ADAS-
Cog, the other primary outcome. There were no significant differences in 
secondary outcomes at six months. There were two types of centre studied, 
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care homes and community services. There were significant differences 
between the centres over and above that explained by centre type.  
 
At three months there were no significant differences on primary outcomes. For 
secondary outcomes, participants randomised to the intervention group had 
significantly better scores than controls on proxy ratings of quality of life (QoL-
AD and DEMQOL) and daily activities. The mean difference on the proxy QoL-
AD was 1.53 (95% CI 0.35 to 2.71; p=0.01); and for the proxy DEMQOL it was 
3.24 (95% CI 0.24 to 6.24; p=0.03). The difference on the ADCS-ADL was 2.64 
(95% CI 0.04 to 5.24; p=0.04).  
 
Quality of maintenance CST programme provision  
To estimate the quality of the maintenance CST provision after each session 
the researchers made ratings on a range of factors related to the successful 
running of the groups: manager’s attitude (0-2), centre atmosphere (0-2), co 
facilitators input (0-2), group atmosphere (0-2), and average attendance at 
sessions (0 = less than 12, 1 = 13–20, 2 = 21-24) with higher scores indicating 
better quality. Centres were divided into low quality (score 0-5) and high quality 
(score 6-10). Eight out of 9 community centres scored as high quality compared to 
only 6 out of 9 care homes. The quality indicator was incorporated into the model 
of analysis with primary outcome results, with baseline score, centre type, age 
and allocation as a fixed effect and within a random effect of centre nested 
within the interaction of quality and type. The analysis showed that both centre 
type and quality of CST provision were not significant in the model using either 
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QoL-AD or ADAS-Cog. There were differences among the centres that could 
not be explained by amount of sessions attended or quality of CST provision. 
 
Maintenance CST/ ACHEI trial platform results 
There were no significant results in relation to primary outcomes. Table 4 shows 
the observed means and SD at baseline. The means and SDs presented at 
follow-ups 1 and 2 are adjusted for the factors and covariates in the fitted model 
including the treatment group by ACHEIs interaction term. The follow-up means 
are standardised to a common baseline mean value. The significance levels 
quoted are for the interaction term. Only for MMSE at both three and six months 
follow up were significant results found. The results show that starting from a 
mean baseline MMSE of 17.8 there was the smallest decrease to 17.25 (95% 
CI 14.63 to 19.87, p=0.03) at follow up 2 in those taking ACHEIS and receiving 
maintenance CST. The largest decrease occurred in those taking ACHEIs but 
with no maintenance CST where the mean was 14.62 (95% CI 11.81 to 17.43, 
p=0.03). There were no other significant differences between groups in any 
other outcome measures. 
 
Between baseline and second follow-up, 92% had no changes to their AChEI 
status with 3 participants stopping (1 in the TAU group and 2 in the maintenance 
CST group) and 11 starting (4 in the TAU group and 7 in the maintenance CST 
group) medication.  There were no differences between the groups 
(intervention and control) in the number of reported adverse events or severity. 
In the intervention group there were five deaths and four withdrawals due to 
health issues. In the usual care group there were six deaths and five 
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withdrawals due to health issues. All events were judged as unrelated to trial 
treatment or assessment contacts by the study trial coordinator and Principal 
Investigator. 
 
DISCUSSION 
Principal findings 
Cognitive stimulation for people with dementia is recognised as being  
effective2,13 and cost-effective26, and CST in particular improves both cognition 
and quality of life.4,13  This trial finds that after the initial CST programme, a 
further 24-week course of weekly Maintenance CST improves quality of life at 
six-months follow-up but confers no additional benefit to cognition. At six 
months it was only participants who reported improved quality of life (a small 
standardised difference of 0.35), whereas at three months only the proxy 
respondents (carers/care staff) noted the improvement (a small standardised 
difference of 0.30). Participants in the intervention group also improved in their 
activities of daily living at three months (a very small standardised difference of 
0.15). There were no significant differences in other outcomes at either three 
or six months.  
The sub-study results suggest that people on ACHEI medication may benefit 
cognitively from maintenance CST, suggesting an additive effect which is in line 
with other studies combining ACHEIs and cognitive stimulation4,8,13,  and the 
Cochrane review2 which found that the effect of cognitive stimulation on 
cognition is over and above the effects of medication alone.  The relevance in 
terms of clinically significant change is less clear. A mean decrease of 1 point 
versus 4 points on the MMSE scale may make a big difference for some people 
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with dementia. The difference might translate into economic benefits since a 
difference of 1 point in the MMSE score may be associated with substantial 
reductions in the costs of caring for people with dementia37. The CST 
programme prior to baseline resulted in mean improvements of 4.4 points on 
the ADAS-Cog and 2.7 points on the MMSE13. Since dementia is associated 
with progressive cognitive decline, there may have been limited potential for 
further cognitive improvement with the maintenance programme. This means 
that at six-months follow-up both groups were likely to have declined from the 
baseline taken after the CST groups finished, and so significant differences in 
cognition were only likely to be found if the usual care (CST only) group had 
declined more than the maintenance group.  
 
Strengths and limitations 
As participants came from nine care homes and nine community services 
across London, Essex and Bedfordshire, this pragmatic trial is likely to be 
generalisable in many respects. However, since participants were almost all 
white it is hard to say how far CST is useful for other ethnic or cultural groups. 
Nevertheless, we have recently adapted the CST programme for a south Asian 
population and successfully run a local group in Hindi and Gujarati. Although 
we took great care to blind our researchers to allocated treatment, we could not 
blind those carers who provided proxy ratings for four measures (ADCS-ADL, 
NPI, QoL-AD and DEMQOL) and this means there is a risk of detection bias. 
Notably these measures provided three of the four significant findings. 
Compared to the original CST study this trial had more diversity in dementia 
severity due to a much higher proportion recruited from the community (50% vs 
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15%). This resulted in the standard deviations of the cognitive measures being 
much higher than in the original trial of CST4. A larger trial might find significant 
differences in cognition after weekly Maintenance CST. However, it may be that 
more frequent groups would be more efficacious. 
This was the first rigorous trial of Maintenance CST. The results are 
inconclusive and suggest that further trials are needed. In particular it would be 
important for other groups to evaluate Maintenance CST.38 
Future research could look in more depth at the optimum frequency and 
duration of CST groups, for example to continue to provide CST twice a week 
(rather than once weekly) for a 6-month period. Another option would be to 
repeat the standard 7-week CST programme after a 4-month break. However, 
this option could be disruptive to the groups, and would not mirror the standard 
approach used in drug interventions that are given without interruption rather 
than as a short course. Meaning of the study for clinicians and policymakers 
 
Clinical implications 
In the previous stage of this study before and after CST (prior to randomisation) 
we found that both cognition and quality of life significantly improved, including 
for those people on ACHEIs.13 However following Maintenance CST at six-
month follow-up we found no significant differences in cognition. There were no 
differences on the ADAS-Cog although the MMSE showed a 0.85 points 
advantage for the Maintenance CST group. This does not suggest that 
Maintenance CST has substantial effects on cognition over and above the 
original benefits of the initial CST programme.2 Generally, MMSE scores in mild 
to moderate dementia generally decrease by 2 to 4 points per year,26. Before 
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the initial CST programme13 (2 months before the start of this RCT) the mean 
ADAS-Cog was 35.0 and the mean MMSE score was 15.8. Eight months later 
at six-month follow-up there was no overall cognitive decline with the mean 
ADAS-Cog scores being 35.9 and 35.3 and the mean MMSE scores being 16.3 
and 15.5 in the treatment and control groups respectively.  From a standardised 
baseline score of 17.75 on the MMSE; in the ACHEI only group, MMSE scores 
fell to 14.60 points in the 6 months of the maintenance CST trial; compared with 
a decrease to 17.25 in the maintenance CST/ACHEI (combined) treatment; and 
a decrease of 16.26 in the maintenance CST only group. This suggests that 
CST may continue to have some degree of protective effect on cognition over 
and above the effects of medication. Other studies using usual care control 
groups have also found that a programme of cognitive stimulation sessions 
over a longer time period can be effective in reducing cognitive decline in 
dementia.27,28  
In chronic conditions quality of life may be more important for older adults than 
disease-specific outcomes and it is a key outcome that interventions for 
dementia should target. Benefits to cognition alone may not be sufficient to 
justify an extensive programme of intervention unless they are accompanied by 
other benefits such as quality of life improvements29. Two recent systematic 
reviews highlighted that there are few well-designed studies on the 
effectiveness of either pharmacological33 or psychosocial34 interventions on 
quality of life. Like other follow up studies we found that individual changes in 
quality of life were apparent for nearly three-quarters of our sample30,31,32.  In 
contrast to the Cochrane review of cognitive stimulation our study found that 
activities of daily living improved at three-month follow-up. However, previous 
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research35 suggests that there may be a correlation between proxy rated quality 
of life and activities of daily living. It might be that the effects of the intervention 
on proxy rated quality of life was linked with the effects on activities of daily 
living. At six month follow up these proxy rated domains showed no difference. 
However, for the person with dementia a temporary improvement in quality of 
life, cognition, or activities of daily living may all be considered worthwhile 
 
Future research  
As this was the first rigorous trial of Maintenance CST, we encourage others to 
implement and evaluate this novel extension in other populations in other 
contexts with other staff. In our research programme we have three further CS 
studies37 Firstly, we are undertaking a pragmatic cluster randomised 
implementation trial to compare staff trained in CST receiving either (1) 
additional support (web support, regular phone support) or (2) no support. This 
will evaluate whether additional staff support results in more CST group 
attendances. Secondly, we are conducting an implementation in practice study 
measuring minimal outcomes (cognition and quality of life) for centres running 
CST/Maintenance CST groups.  Lastly, we have developed a version of CST 
for use by the family carer (individual CST) and this is currently being evaluated 
in a large multicentre trial funded by the National Institute of Health 
Research/Health Technology Assessment programme.  
 
CONCLUSIONS 
Standard CST can improve cognition and quality of life. This trial indicates that 
weekly Maintenance CST over 24 weeks adds little beyond the basic CST 
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programme. Nevertheless, over the 8 months (from the original baseline before 
2 months of CST and the six-month follow-up), the average cognitive decline in 
both the maintenance CST and usual care groups was considerably less than 
would normally be expected in practice suggesting the original CST programme 
had some residual beneficial effect. Further research should evaluate whether 
long-term CST should be provided more frequently than once a week. Over the 
8 months (from the original baseline before 2 months of CST and the 6-month 
follow-up), the average cognitive decline in both the maintenance CST and TAU 
groups was considerably less than would normally be expected in practice 
suggesting the original CST programme had some residual beneficial effect. 
Maintenance CST may offer short and long term benefits to quality of life. The 
sub study of maintenance CST with ACHEIs provides initial evidence that 
maintenance cognitive stimulation therapy in combination with ACHEI 
medication may have longer term benefits to cognition. Pharmacological and 
psychosocial interventions may potentially work better together than either 
alone.  
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What this paper adds 
What is already known on this subject  
 The Cochrane Review of cognitive stimulation found that it can 
improve cognition and quality of life for people with dementia. 
 There is only limited  evidence about the effects of longer term 
cognitive stimulations programmes 
 Little is known about how long or how often to continue cognitive 
stimulation sessions beyond a short term programme 
What this study adds  
 This trial suggests that maintenance cognitive stimulation may improve 
quality of life, but not cognition over six months  
 There is initial evidence to suggest that maintenance cognitive 
stimulation therapy in combination with ACHEI medication may have 
longer term benefits to cognition 
 Cognitive decline was less than expected for both the CST only (usual 
care) and CST/maintenance CST (intervention) groups  
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Figure 1. Consort flowchart of participants’ progress 
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Baseline (n=236) 
Randomised (n = 236) 
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Allocated to control 
(n =113) 
 
Lost to follow up (n =9)   Death (n= 3 )  Health problems (n= 2 )  Declined to continue (n= 4 ) 
Lost to follow up (n =9)   Death (n= 3 )  Health problems (n= 2 )  Declined to continue (n= 4 ) 
Assessed at 3 months 
(n =114) 
Assessed at 3 months 
(n =104) 
 
Lost to follow up (n =8)   Death (n= 2 )  Health problems (n= 2 )  Declined to continue (n= 4 ) 
 
Lost to follow up (n =11)   Death (n= 3)  Health problems (n= 3)  Declined to continue (n= 3 )  Other (n=2) 
Assessed at 6 months 
(n =106) 
 
Assessed at 6 months 
(n =93) 
Follow up 
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Follow up 
at 3 months 
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Table 1.  Baseline characteristics of 236 participants in maintenance CST trial 
 
Participants at Baseline 0  - Before start of CST groups 272 
Total lost from the beginning of CST groups 36 
 
Reason for withdrawal  
Did not like CST groups and wanted to withdraw  17 (49%) 
Health issues 15 (40%) 
Difficulties with group time or other participants  2 (6%) 
 Moved to a different care home   2 (6%) 
Participants at Baseline 1 - After completion of CST groups  236 
 
 34 
Table 2. Baseline characteristics of 236 participants by allocated group 
 
 Intervention (n=123) Control (n=113)  
Characteristics Number (%) Number (%) 
 
Female 80 (65%)  70 (62% ) 
Ethnicity: white 111 (90%)  104 (92%) 
Marital status (widow) 54 (44%)  57 (50%) 
Dementia diagnosis (AD) 38 (31%)  35 (31%) 
On AChEIs  42 (34%)  34 (30%) 
In Care Home 51 (41%)  50 (44%) 
 
 Mean (SD) Mean (SD) 
Age (years):  82.7 (7.9) 83.5 (7.2) 
ADAS-Cog score 31.1 (14.6) 33.2 (13.0) 
QoL-AD score 36.1 (4.8) 36.5 (5.7) 
MMSE score 17.8 (5.6) 17.8 (5.4) 
DEMQOL score 94.8 (10.9) 95.1 (11.7) 
NPI  score 13.8 (12.9) 11.3 (9.1) 
ADCS-ADL score 42.7 (17.2) 41.5 (18.1) 
Proxy QoL-AD score 33.7 (5.9) 33.3 (4.9) 
Proxy DEMQOL score 102.2 (13.5) 102.2 (11.2) 
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Table 3. Effects of Maintenance CST on adjusted imputed outcomes at primary and secondary end points  
 Primary end point - 6 month follow up Secondary end point  3-month follow up  
Adjusted 
outcomes 
Treatment Control Differencea Significance 
level 
Treatment Control Differencea Significance 
level 
Mean (SE) Mean (SE) Mean (SE)  Mean (SE) Mean (SE) Mean (SE)  
ADAS-Cogb 35.94 (2.79) 35.29 (2.85) -0.65 (1.55) .68 35.32 (2.56) 34.47 (2.59) -0.85 (1.29) .51 
QoL-ADc 35.62 (1.43) 33.84 (1.53) 1.78 (0.91) .05 34.29 (1.03) 33.97 (1.04) 0.32 (0.61) .60 
MMSEc 16.34 (1.21) 15.49 (1.25) 0.85 (0.58) .15 16.09 (0.88) 15.79 (0.91) 0.30 (0.52)  .57 
DEMQOLc 89.13 (3.55) 88.83 (3.56) 0.30 (1.52) .84 89.85 (2.34) 90.71 (2.38) -0.86 (1.31) .51 
NPIb 18.76 (3.78) 20.35 (3.94) 1.58 (2.16) .47 14.71 (2.84) 16.18 (2.76) 1.47 (1.55) .34 
ADCS-ADLc 43.29 (2.88) 42.35 (2.87) 0.94 (1.51) .53 43.58 (2.32) 40.94 (2.32) 2.64 (1.30) .04 
Proxy QoL-ADc 34.12 (1.41) 34.05 (1.41) 0.07 (0.74) .93 33.93 (1.05) 32.40 (1.07) 1.53 (0.59) .01 
Proxy DEMQOLc 97.75 (3.23) 96.61 (3.21) 1.13 (1.71) .51 101.36 (2.67) 98.12 (2.67) 3.24 (1.50) .03 
a Positive differences favour maintenance CST.  
b Lower scores show better outcome 
c Higher scores show better outcome 
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Table 4. Effects of Maintenance CST on adjusted imputed outcomes at primary  
and secondary end point according to ACHEI treatment.  The significance levels quoted are  
for the interaction term of treatment group and receipt of ACHEIs.  
   Baseline 3 months  6 months  
 Group n Mean SE 
Model  
adjusted 
mean 
SE Interaction p 
Model 
adjusted 
mean 
SE Interaction p 
ADAS-Cog      .13   .71 
 ACHEI 34  31.29 2.09 37.05 2.84  36.52 3.53  
 TAU 79 34.03 1.5 32.35 2.68  34.67 2.97  
 ACHEI/MCST 42 28.65 1.78 36.55 3.16  35.77 3.28  
 MCST  81 32.4 1.77 33.85 2.57  35.99 2.98  
QOL-AD       .97   .48 
 ACHEI 34  37.73 .76 32.81 1.23  33.94 1.86  
 TAU 79 35.99 .69 35.13 1.09  33.81 1.52  
 ACHEI/MCST 42 37.08 .77 33.14 1.27  34.72 1.7  
 MCST  81 35.62 .53 35.45 1.05  36.07 1.44  
NPI       .99   .26 
 ACHEI 34  12.13 1.62 17.23 3.28  23.78 4.54  
 TAU 79 11 1.01 15.12 2.86  17.15 4.11  
 MCST/ACHEI 42 16.15 2.73 15.85 3.39  18.21 4.47  
 MCST  81 12.65 1.05 13.61 2.82  17.49 3.79  
ADL       .80   .80 
 ACHEI 34  44.03 2.88 41.51 2.79  42.45 3.34  
 TAU 79 40.42 2.10 40.37 2.47  42.22 3.04  
 MCST/ACHEI 42 48.24 2.87 43.83 2.87  43.91 3.46  
 MCST only 81 39.78 1.75 43.17 2.34  42.91 2.92  
MMSE      .03   .03 
 ACHEI 34  18.85 .79 15.26 1.08  14.62 1.40  
 TAU 79 17.33 .63 16.25 .92  16.26 1.28  
 MCST/ACHEI 42 18.27 .84 17.17 1.06  17.25 1.33  
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 MCST  81 17.55 .64 15.77 .88  16.26 1.26  
DEMQOL      .92   .97 
 ACHEI 34  97.90 1.51 89.13 2.81  87.93 3.90  
 TAU 79 93.86 1.42 92.25 2.51  89.75 3.74  
 ACHEI/MCST 42 97.36 1.53 88.99 2.89  87.88 3.86  
 MCST  81 93.49 1.26 91.04 2.37  90.22 3.69  
 
